Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Saccharomyces boulardii

Saccharomyces boulardii (CNCM I-745) · also known as Saccharomyces boulardii, Probiotic yeast, S. boulardii, Florastor

A non-pathogenic yeast that tolerates antibiotics and is often used to prevent antibiotic-associated diarrhea. In experiments, its protease can break down Clostridioides difficile toxin, but it cannot be relied on to fully inactivate the toxin in clinical use. Most of the evidence for its mucosal immune and barrier effects comes from animal and cell studies.

Typical dose: 250–500 mg/day, labeled to provide about 5–10 billion CFU of live yeast cells. The actual live count varies by strain and formulation, so go by the product label. Swallow with warm water no hotter than 40°C.
Absorption and forms: Saccharomyces boulardii is a fungus, so it naturally tolerates antibacterial drugs such as amoxicillin, cephalosporins and metronidazole, and can be taken at the same time as antibiotics. Its survival is, however, affected by antifungal drugs. Colonization is transient: after you stop taking it, the yeast is cleared naturally in stool within 3–5 days.

Clinical uses and human evidence

Diarrhea (including antibiotic-associated diarrhea)

BeneficialGrade B · Moderate evidence
Studies (2)
  1. Szajewska 2015 · Aliment Pharmacol Ther · Meta-analysis · n=4780 — Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea
  2. Ehrhardt 2016 · Open Forum Infect Dis · RCT · n=477 — Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial

Irritable bowel syndrome

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Choi 2011 · J Clin Gastroenterol · RCT · n=67 — A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life

Mechanisms of action

Epithelial tight junction (ZO-1 / Occludin) reinforcement and barrier repair

★★★☆☆Mechanism evidence: grade CSecondary target

The protease secreted by the yeast can break down toxins from pathogenic E. coli and Clostridioides difficile in vitro. In a mouse colitis model, barrier markers such as ZO-1 and occludin improved, but human studies did not measure tight junction proteins directly. Toxin breakdown and tight junction repair are two different actions.

References (2)
  1. Dong et al. 2019 · Mouse study: barrier markers such as ZO-1 and occludin improved in a colitis model
  2. Garcia Vilela et al. 2008 · Human randomized trial: intestinal permeability improved in patients in remission from Crohn’s disease, but tight junction proteins were not measured directly

Pattern recognition receptor (PRR) immune surveillance and trained immunity

★★☆☆☆Mechanism evidence: grade DSecondary target

Mannans and β-glucans in the yeast cell wall can be recognized by Dectin-1 in vitro. In mice, the intestinal antitoxin IgA response increased, but this does not prove pattern recognition receptor (PRR) signaling or trained immunity in humans. There is also no basis for claims that pIgR is up-regulated several-fold.

References (2)
  1. Smith et al. 2016 · In-vitro study (human dendritic cells): Dectin-1 is involved in recognizing the Saccharomyces boulardii cell wall
  2. 2001 · Mouse study: the intestinal antitoxin IgA response increased after yeast feeding, but human PRR training has not been shown

Safety and drug interactions

Do not use in people with long-term central venous catheters, profound immunodeficiency, or critical illness in intensive care, because of the risk of fungal bloodstream infection. Also do not use in people allergic to yeast.

With Immunosuppressants High risk

Cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil

Saccharomyces boulardii is a live yeast, and fungal bloodstream infections have been reported in people with suppressed immunity, such as organ transplant recipients. Do not take it on your own initiative while on immunosuppressants; if you need it, consult your transplant team first.

Open in the interactive app ›